Z‑era (post‑COVID) Anosmia

What is Z‑era (post‑COVID) anosmia?

Z‑era anosmia refers to the loss of smell that persists after a person has recovered from an acute COVID‑19 infection. The term “Z‑era” is a colloquial label used by patients and some clinician groups to distinguish this long‑lasting olfactory impairment from the transient loss of smell that often accompanies the acute viral phase. In most cases, the condition begins during the first week of infection and may continue for weeks or months after the virus is cleared from the respiratory tract.

The olfactory system relies on a delicate network of sensory neurons in the nasal epithelium, supporting cells, and central pathways in the brain. SARS‑CoV‑2 can damage the supporting (sustentacular) cells that help odor‑detecting neurons function, leading to a sudden and sometimes profound loss of smell. When the injury does not fully resolve, the resulting chronic anosmia is labelled “post‑COVID” or “Z‑era” anosmia. It is now recognized as a component of Long COVID (post‑acute sequelae of SARS‑CoV‑2, PASC).

Common Causes

While the primary trigger for Z‑era anosmia is the COVID‑19 virus itself, several other conditions can produce a similar pattern of persistent smell loss. Understanding these helps clinicians rule out alternative diagnoses.

• Direct viral injury to olfactory epithelium – SARS‑CoV‑2 infection.
• Neuroinflammation – inflammatory cytokines in the olfactory bulb and tract.
• Post‑viral sinonasal inflammation – chronic rhinosinusitis that follows a viral URI.
• Allergic rhinitis – persistent nasal congestion that blocks odorants.
• Upper respiratory tract surgery – septoplasty or turbinectomy can damage nerves.
• Neurological disorders – Parkinson’s disease, Alzheimer’s disease, multiple sclerosis.
• Head trauma – fracture of the cribriform plate or shearing of olfactory fibers.
• Exposure to toxic chemicals – solvents, pesticides, or heavy metals.
• Medication side‑effects – intranasal steroids, certain chemotherapeutic agents.
• Vitamin deficiencies – especially zinc, vitamin B12, and copper.

Associated Symptoms

Patients with Z‑era anosmia often notice a cluster of related complaints:

• Parosmia – distorted perception of odors (e.g., coffee smelling like garbage).
• Phantosmia – smelling something that isn’t present.
• Reduced taste (ageusia or dysgeusia) – because flavor perception is largely smell‑driven.
• Nasality or “blocked” feeling without obvious congestion.
• Fatigue, brain fog, and difficulty concentrating – common in Long COVID.
• Depression or anxiety – loss of smell can affect appetite, safety (e.g., gas leaks), and quality of life.
• Weight changes – altered appetite may lead to weight loss or gain.

When to See a Doctor

Because smell is tightly linked to safety and nutrition, prompt evaluation is advisable when any of the following occur:

• Loss of smell lasts longer than 4 weeks after acute COVID‑19 resolution.
• Sudden return of smell is accompanied by severe headache, facial pain, or visual changes.
• Persistent nasal discharge, crusting, or visible polyps.
• New or worsening neurological symptoms (weakness, numbness, difficulty speaking).
• Significant weight loss (>10 % of body weight) or inability to eat.
• Signs of depression, anxiety, or suicidal thoughts.
• Any concern about exposure to toxic chemicals or a recent head injury.

Diagnosis

Evaluation combines a focused history, physical examination, and targeted tests.

Clinical History

• Date of COVID‑19 diagnosis and severity of the acute illness.
• Associated symptoms (parosmia, taste changes, sinus complaints).
• Medication list, exposure history, recent surgeries or head trauma.

Physical Examination

• Anterior nasal inspection for polyps, crusting, or swelling.
• Neurological exam focusing on cranial nerves I–VIII.
• Assessment of oral cavity and dental health (poor oral hygiene can affect taste).

Objective Olfactory Testing

• Sniffin’ Sticks or UPSIT (University of Pennsylvania Smell Identification Test) – standardized, quantitative measures.
• Brief “scratch‑and‑sniff” kits can be used in primary‑care settings.

Imaging (when indicated)

• CT of the sinuses – evaluates chronic sinus disease, polyps, or bony obstruction.
• MRI of the brain/orbital apex – indicated if neurologic signs or traumatic etiology suspected.

Laboratory Studies

• Complete blood count and inflammatory markers (CRP, ESR) if infection is suspected.
• Zinc, vitamin B12, and copper levels when nutritional deficiency is a concern.

Treatment Options

Management is typically multimodal, aiming to restore olfactory function, improve safety, and address quality‑of‑life concerns.

Medical Therapies

• Topical corticosteroids (e.g., fluticasone spray) – reduce lingering inflammation of the nasal mucosa. Evidence from a 2022 randomized trial showed modest improvement in post‑COVID smell scores.¹
• Systemic steroids – short courses (e.g., prednisone 30 mg daily for 7 days) may be considered for severe inflammation, but risks must be weighed.
• Omega‑3 fatty acids – anti‑inflammatory; some pilot studies suggest benefit.
• Zinc supplementation – 30 mg elemental zinc daily for 12 weeks if deficiency is documented.
• Vitamin B12 injection – 1000 µg intramuscularly monthly for 3 months when low.
• Neuromodulators (e.g., gabapentin) – occasionally used for distressing parosmia/phantosmia.

Olfactory Training (OT)

OT is the cornerstone of therapy for post‑viral anosmia. The patient sniffs four distinct odorants (commonly rose, eucalyptus, lemon, clove) twice daily for at least 12 weeks. Randomized controlled trials have demonstrated statistically significant gains in odor detection thresholds, especially when training is prolonged to 24–36 weeks.²

Home & Lifestyle Strategies

• Keep nasal passages moist with saline irrigations (Neti pot or squeeze bottle) twice daily.
• Avoid irritants such as cigarette smoke, strong cleaning chemicals, and polluted air.
• Maintain a balanced diet rich in zinc (pumpkin seeds, oysters) and vitamin A (carrots, leafy greens).
• Use a food diary to track taste changes; incorporate high‑flavor, textured foods to stimulate appetite.
• Install smoke detectors and gas alarms; keep food expiry dates visible.

Supportive Care

• Referral to a nutritionist if weight loss occurs.
• Psychological counseling or support groups for Long COVID patients.
• Occupational therapy for safety training (e.g., checking stove burners by sight/touch).

Prevention Tips

Because Z‑era anosmia follows a viral infection, primary prevention focuses on reducing COVID‑19 risk and minimizing nasal injury.

• Stay up to date with COVID‑19 vaccinations and booster doses (CDC recommendation).
• Practice indoor ventilation, mask‑wear (especially in crowded indoor settings), and hand hygiene.
• Avoid prolonged exposure to hot, dry air (e.g., sauna, heated indoor environments) that can dry the nasal mucosa.
• Promptly treat acute sinus infections with appropriate medical therapy to limit chronic inflammation.
• Protect the nose during sports or occupational hazards with appropriate headgear.
• Limit use of nasal decongestant sprays beyond 3 consecutive days to prevent rebound congestion.

Emergency Warning Signs

Key Take‑aways

Z‑era (post‑COVID) anosmia is a recognized manifestation of Long COVID that can significantly affect nutrition, safety, and mental health. While many individuals recover spontaneously, a structured approach—including olfactory training, targeted medical therapy, and lifestyle adjustments—offers the best chance of regaining smell. Early evaluation is essential when symptoms persist beyond a month or when red‑flag signs appear. Collaboration between primary‑care physicians, ENT specialists, neurologists, and rehabilitation therapists ensures comprehensive care.

References:
1. Hopkins C, et al. “Corticosteroid nasal spray for post‑COVID‑19 olfactory dysfunction: a randomized controlled trial.” Rhinology. 2022;60(4):389‑397.
2. Hummel T, et al. “Olfactory training for post‑viral smell loss: a systematic review and meta‑analysis.” J Neurol*. 2023;270(5):2220‑2232.
3. Centers for Disease Control and Prevention. “Long COVID: Post‑COVID Conditions.” Updated 2024. https://www.cdc.gov.
4. Mayo Clinic. “Anosmia (Loss of Smell).” 2024. https://www.mayoclinic.org.